US VP Harris defends abortion pill facing legal attack

Published 02/24/2023, 05:07 AM
Updated 02/24/2023, 01:12 PM
© Reuters. FILE PHOTO: U.S. Vice President Kamala Harris speaks, during the Munich Security Conference (MSC) in Munich, Germany February 18, 2023. REUTERS/Wolfgang Rattay/

By Trevor Hunnicutt and Jeff Mason

WASHINGTON (Reuters) - Vice President Kamala Harris defended the abortion drug mifepristone on Friday, calling attacks against it another attempt to attack fundamental rights in the United States, as some activist groups work to end American sales of the pill.

Anti-abortion groups have brought cases against the U.S. Food and Drug Administration (FDA) claiming the agency used an improper process to approve mifepristone in 2000 and did not adequately consider its safety for minors.

Medication abortion has drawn increasing attention since the U.S. Supreme Court last year reversed its landmark 1973 Roe v. Wade ruling, which had guaranteed abortion rights nationwide.

Democratic President Joe Biden directed federal agencies to expand access to medication abortion in response to the decision, which has allowed more than a dozen Republican-led states to adopt new abortion bans.

Harris met with reproductive rights groups on the topic at the White House, and said attacking the drug is akin to going after the very foundation of the American public health system and is not just an attack on women's fundamental freedoms.

She said there are "partisan" and "political attacks" questioning the legitimacy of the scientists and doctors who had conducted research on the drug, which was approved 20 years ago.

"We are now in a situation where there is an attempt to further attack fundamental rights to healthcare, in that there is an attack that has been placed against the ability of doctors to prescribe and people to receive medication to allow them to make decisions about their reproductive health," Harris said.

Administration officials fear that courts could disrupt access to the medication, which is also used to help women dealing with miscarriages.

Mifepristone is approved for medication abortion in the first 10 weeks of pregnancy in combination with another drug, misoprostol. Medication abortion accounts for more than half of U.S. abortions.

© Reuters. FILE PHOTO: U.S. Vice President Kamala Harris speaks, during the Munich Security Conference (MSC) in Munich, Germany February 18, 2023. REUTERS/Wolfgang Rattay/

The FDA has said that pulling mifepristone from the market would force women to have unnecessary surgical abortions and greatly increase wait times at already overburdened clinics.

Major medical organizations, including the American College of Obstetricians and Gynecologists, weighed in on the side of the government, saying mifepristone "has been thoroughly studied and is conclusively safe."

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.